Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study
Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study
复制标题
滤泡性淋巴瘤患者的同种异体骨髓移植：单中心研究
DOI：
10.1038/sj.bmt.1703625
复制
发表时间：
2002
影响因子：
4.8
通讯作者：
F. Morschhauser
中科院分区：
文献类型：
--
作者：
I. Yakoub;A. Fawaz;O. Folliot;G. Guillerm;B. Quesnel;P. Fenaux;F. Bauters;J. Jouet;F. Morschhauser
同种异体 BMT 对滤泡性淋巴瘤的作用仍有待确定。 1995年至2000年，我中心16例滤泡性淋巴瘤患者接受了同种异体BMT。移植时，2 名患者处于完全缓解状态，11 名患者处于部分缓解状态，3 名患者患有难治性疾病。十四名患者使用标准清髓性预处理方案进行移植，两名患者使用非清髓性预处理方案进行移植。 BMT 后中位随访时间为 1184 天（范围 403-1999 天），其中 11 名患者存活，5 名患者死于移植相关死亡。 BMT 后 284+ 至 1022+ 天（中位 560+ 天）的 8 名患者仍保持 CR。两名患者在 BMT 后 63 天和 1073 天复发。他们在抢救治疗后进一步完全缓解，并在 BMT 后分别存活 403 天和 1224 天。一名自体重建患者在 BMT 后从未达到 CR。他接受了挽救性化疗，但仅通过随后的利妥昔单抗治疗才达到 CR，并且在移植后 1999 天仍然活着。预计 2 年总生存率和无事件生存率分别为 68% 和 55%。诊断时年龄大于 37 岁、受者 CMV 血清学阳性和诊断时 ECOG 体能状态⩾1 与较短的总生存期相关（分别为 P = 0.05、P = 0.009 和 P = 0.03）。诊断时的安娜堡 III-IV 期与较短的无事件生存期相关 (P < 0.04)。同种异体 BMT 似乎对滤泡性淋巴瘤患者有效。然而，早期移植相关死亡率相对较高，强调需要定义适应症并使用涉及毒性较小的移植程序的前瞻性方案。
The role of allogeneic BMT for follicular lymphoma remains to be established. From 1995 to 2000, 16 patients with follicular lymphoma underwent allogeneic BMT at our center. At the time of transplantation, two patients were in complete remission, 11 in partial remission and three had refractory disease. Fourteen patients were transplanted using a standard myeloablative conditioning regimen and two a nonmyeloablative conditioning regimen. With a median follow-up of 1184 days (range 403–1999 days) after BMT, 11 patients were alive, whereas five died of transplant-related mortality. Eight patients remained in CR 284+ to 1022+ days (median 560+ days) after BMT. Two patients relapsed 63 and 1073 days after BMT. They achieved a further complete remission after salvage treatment and remained alive 403 and 1224 days after BMT, respectively. One patient with autologous reconstitution had never been in CR after BMT. He was retreated with salvage chemotherapy but only achieved CR with subsequent rituximab treatment and was still alive, 1999 days after transplantation. The estimated 2-year overall survival and event-free survival rates were 68% and 55%, respectively. Age greater than 37 years at diagnosis, positive recipient CMV serology and ECOG performance status ⩾1 at diagnosis were associated with shorter overall survival (P = 0.05, P = 0.009 and P = 0.03, respectively). Ann Arbor III–IV stage at diagnosis was associated with shorter event-free survival (P < 0.04). Allogeneic BMT seems to be effective for patients with follicular lymphoma. However, the relatively high rate of early transplant-related mortality emphasizes the need to define indications and use prospective protocols involving a less toxic transplant procedure.
影响因子：
11.2
作者：
P. Carbone;H. Kaplan;K. Musshoff;D. Smithers;M. Tubiana
通讯作者：
P. Carbone;H. Kaplan;K. Musshoff;D. Smithers;M. Tubiana
低度非霍奇金淋巴瘤复发后的生存：对骨髓移植的影响。
DOI：
10.1200/jco.1992.10.6.942
发表时间：
1992
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Weisdorf,DJ;Andersen,JW;Glick,JH;Oken,MM
通讯作者：
Oken,MM
对 69 名有低度 B 细胞非霍奇金淋巴瘤病史的患者进行自体骨髓移植。
影响因子：
20.3
作者：
Freedman,AS;Ritz,J;Neuberg,D;Anderson,KC;Rabinowe,SN;Mauch,P;Takvorian,T;Soiffer,R;Blake,K;Yeap,B
通讯作者：
Yeap,B